 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--- GRPH GraphiteBio--Graphite Bio, Inc. Nasdaq: GRPH, a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today the presentation of preclinical data for GPH101, an investigational therapy designed to directly correct the genetic mutation responsible for sickle cell disease SCD. Data were presented at the 49th Annual Sickle Cell Disease Association of America 